Expression and function of IL‐10R in mononuclear cells from patients with systemic lupus erythematosus

References

• Moore K. W., O'Garra A., de Waal M. R., Vieira P., Mosmann T. R. Interleukin‐10. Annu Rev Immunol 1993; 11: 165–83
   PubMed Web of Science ®Google Scholar
• Mehrotra P. T., Donnelly R. P., Wong S., Kanegane H., Geremew A., Mostowski H. S., et al. Production of IL‐10 by human natural killer cells stimulated with IL‐2 and/or IL‐12. J Immunol 1998; 160: 2637–44
   PubMedGoogle Scholar
• Itoh K., Hirohata S. The role of IL‐10 in human B cell activation, proliferation and differentiation. J Immunol 1995; 154: 4341–50
   PubMed Web of Science ®Google Scholar
• Mocellin S., Panelli M. C., Wang E., Nagorsen D., Marincola F. M. The dual role of IL‐10. Trends Immunol 2003; 24: 36–43
   PubMed Web of Science ®Google Scholar
• Georgeson L., Kishna‐Vakkalanka R., Elkon K. B., Crow M. K. Interleukin‐10 promotes activation‐induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997; 100: 2622–33
   PubMedGoogle Scholar
• Moore K. W., de Waal M. R., Coffman R. L., O'Garra A. Interleukin‐10 and the interleukin‐10 receptor. Annu Rev Immunol 2001; 19: 683–756
   PubMed Web of Science ®Google Scholar
• Liu Y., Wei S. H., Ho A. S. Y., de Waal M. R., Moore K. W. Expression, cloning and characterization of a human IL‐10 receptor. J Immunol 1994; 152: 1821–9
   PubMed Web of Science ®Google Scholar
• Liu K. D., Gaffen S. L., Goldsmith M. A. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 1998; 10: 271–8
   PubMed Web of Science ®Google Scholar
• Fimbloom D. S., Winestock K. D. IL‐10 induces the tyrosine phosphorylation of Tyk2 and Jak1 and the differential assembly of STAT1α and STAT3 complexes in human T cells and monocytes. J Immunol 1995; 155: 1079–90
   PubMedGoogle Scholar
• Riley J. K., Takeda K., Akira S., Schreiber R. D. Interleukin‐10 receptor signaling through the JAK/STAT pathway. Requirement for two distinct receptors‐derived signals for anti‐inflammatory action. J Biol Chem 1999; 274: 16513–21
   PubMed Web of Science ®Google Scholar
• Mills J. A. Systemic lupus erythematosus. N Engl J Med 1994; 330: 1871–9
   PubMed Web of Science ®Google Scholar
• Julkunen H., Salonen E. M., Walle T. K., Miettinen A. Anti‐nucleosome antibodies in the diagnosis of systemic lupus erythematosus. Scand J Rheumatol 2005; 34: 122–4
   PubMedGoogle Scholar
• Lispky P. E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764–6
   PubMedGoogle Scholar
• Tsokos G. C. Systemic lupus erythematosus, R. G Lahita. Academic Press, New York 1998; 17–54
   Google Scholar
• Portales‐Pérez D., González‐Amaro R., Abud‐Mendoza C., Sánchez‐Armass S. Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus. Lupus 1997; 6: 48–56
   PubMed Web of Science ®Google Scholar
• Liossis S. N., Ding X. Z., Dennis G., Tsokos G. C. Altered pattern of TCR/CD3‐mediated protein‐tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998; 101: 1448–57
   PubMed Web of Science ®Google Scholar
• Tsokos G. C., Liosis S. N. C. Immune cell signaling defects in lupus; activation, anergy and death. Immunol Today 1999; 20: 119–24
   PubMedGoogle Scholar
• Richaud‐Patin Y., Alcocer‐Varela J., Llorente L. High levels of Th2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995; 47: 267–72
   PubMedGoogle Scholar
• Csiszar A., Nagy G. Y., Gergely P., Pozsonyi T., Pocsik E. Increased interferon‐gamma (IFN‐γ), IL‐10 and decreased IL‐4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000; 122: 464–70
   PubMed Web of Science ®Google Scholar
• Llorente L., Richard‐Patin Y., Wijdenes J., Alcocer‐Varela J., Maillot M. C., Durand‐Gasselin I., et al. Spontaneous production of interleukin‐10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 421–7
   PubMed Web of Science ®Google Scholar
• Llorente L., Zou W., Levy Y., Richaud‐Patin Y., Wijdenes J., Alcocer‐Varela J., et al. Role of interleukin‐10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839–44
   PubMed Web of Science ®Google Scholar
• Park Y. B., Lee S. K., Kim D. S., Lee J., Lee C. H., Song C. H. Elevated interleukin‐10 levels correlate with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 283–8
   PubMed Web of Science ®Google Scholar
• Grondal G., Gunnarsson I., Ronnelid J., Rogberg S., Klareskog L., Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18: 565–70
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R., Haanen J., Spits H., Roncarolo M. G., te Velde A., Figdor C., et al. Interleukin 10 (IL‐10) strongly reduces antigen‐specific human T cell proliferation by diminishing the antigen‐presenting capacity of monocytes via down regulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915–24
   PubMed Web of Science ®Google Scholar
• Cairns A. P., Crockrad A. D., Bell A. L. Interleukin‐10 receptor expression in systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: 83–6
   PubMedGoogle Scholar
• Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7
   PubMed Web of Science ®Google Scholar
• Guzmán J., Cardiel M. H., Arce‐Salinas A., Sánchez‐Guerrero J., Alarcón‐Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551–8
   PubMed Web of Science ®Google Scholar
• Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and one of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest (Suppl) 1968; 97: 77–89
   PubMedGoogle Scholar
• González‐Amaro R., Portales‐Pérez D. P., Baranda L., Abud‐Mendoza C., Llorente L., Richaud‐Patin Y., et al. Role of IL‐10 in the abnormalities of early cell activation events of lymphocytes from patients with systemic lupus erythematosus. J Autoimmun 1998; 11: 395–402
   PubMedGoogle Scholar
• Llorente L., Richaud‐Patin Y., Garcia‐Padilla C., Claret E., Jakez‐Ocampo J., Cardiel M. H., et al. Clinical and biologic effects of anti‐interleukin‐10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790–800
   PubMed Web of Science ®Google Scholar
• Makuta Y., Sonoda Y., Yamamoto D., Funakoshi‐Tago M., Aizu‐Yokota E., Takebe Y., et al. Interleukin‐10‐induced CCR5 expression in macrophage like HL‐60 cells: involvement of Erk1/2 and STAT‐3. Biol Pharm Bull 2003; 26: 1076–81
   PubMedGoogle Scholar
• Niiro H., Otsuka T., Ogami E., Yamaoka K., Nagano S., Akahoshi M., et al. MAP kinase pathways as a route for regulatory mechanisms of IL‐10 and IL‐4 which inhibit COX‐2 expression in human monocytes. Biochem Biophys Res Commun 1998; 18: 200–5
   Google Scholar
• Shuai K., Liu B. Regulation of JAK‐STAT signaling in the immune system. Nat Rev Immunol 2003; 3: 900–11
   PubMed Web of Science ®Google Scholar
• Myers M. P., Andersen J. N., Cheng A., Tremblay M. L., Horvath C. M., Parisien J. P., et al. Tyk2 and Jak2 are substrates of protein‐tyrosine phosphatase 1B. J Biol Chem 2001; 276: 47771–4
   PubMed Web of Science ®Google Scholar
• Chung C. D., Liao J., Liu B., Rao X., Jay P., Berta P., et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278: 1803–5
   PubMed Web of Science ®Google Scholar
• Gergely P., Jr., Niland B., Gonchoroff N., Pullmann R., Jr., Phillips P. E., Perl A. Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL‐10 signaling in patients with systemic lupus erythematosus. J Immunol 2002; 169: 1092–101
   PubMed Web of Science ®Google Scholar
• Han G. M., Chen S. L., Shen N., Ye S., Bao C. D., Gu Y. Y. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177–86
   PubMed Web of Science ®Google Scholar
• Rus V., Chen H., Zernetkina V., Magder L. S., Mathai S., Hochberg M. C., et al. Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease. Clin Immunol 2004; 112: 231–4
   PubMed Web of Science ®Google Scholar
• Bennett L., Palucka A. K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711–23
   PubMed Web of Science ®Google Scholar
• Alexander J. J., Saxena A. K., Bao L., Jacob A., Haas M., Quigg R. J. Prominent renal expression of a murine leukemia retrovirus in experimental systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 2869–77
   PubMed Web of Science ®Google Scholar
• Rozzo S. J., Allard J. D., Choubey D., Vyse T. J., Izui S., Peltz G., et al. Evidence for an interferon‐inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001; 15: 435–43
   PubMed Web of Science ®Google Scholar
• Sheriff A., Gaipl U. S., Voll R. E., Kalden J. R., Herrmann M. Apoptosis and systemic lupus erythematosus. Rheum Dis Clin North Am 2004; 30: 505–27
   PubMedGoogle Scholar
• Mok C. C., Lau C. S. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481–90
   PubMed Web of Science ®Google Scholar
• Williams L. M., Ricchetti G., Sarma U., Smallie T., Foxwell B. M. J. Interleukin‐10 suppression of myeloid activation. A continuing puzzle. Immunology 2004; 113: 281–92
   PubMed Web of Science ®Google Scholar
• Schotte H., Willeke P., Tidow N., Domschke W., Assmann G., Gaubitz M., et al. Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA‐DR3. Scand J Rheumatol 2005; 34: 114–21
   PubMed Web of Science ®Google Scholar